"description","name","rationale","label","instanceType","uuid:ID","id"
"The main design for the study","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign","23307f35-efb8-4399-a887-d72ad80b7c19","StudyDesign_1"
